Novel therapies for high-grade gliomas: A vision for future
The treatment for high-grade glioma remains an enigma. The standard treatment using surgery, radiation therapy and chemotherapy for such highly malignant lesions has only yielded modest results, in terms of survival and improving the quality of life of patients. Less than 10% of such patients surviv...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2012-01-01
|
| Series: | Indian Journal of Neurosurgery |
| Subjects: | |
| Online Access: | http://www.thieme-connect.de/DOI/DOI?10.4103/2277-9167.94372 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850162890217095168 |
|---|---|
| author | Vivek Tandon Subhashree Mahapatra Ashok Kumar Mahapatra |
| author_facet | Vivek Tandon Subhashree Mahapatra Ashok Kumar Mahapatra |
| author_sort | Vivek Tandon |
| collection | DOAJ |
| description | The treatment for high-grade glioma remains an enigma. The standard treatment using surgery, radiation therapy and chemotherapy for such highly malignant lesions has only yielded modest results, in terms of survival and improving the quality of life of patients. Less than 10% of such patients survive beyond two years. All conventional therapies have failed to increase the survival beyond this extent. There has been a growing interest in the molecular approaches for the treatment of high-grade gliomas which include gene therapy, oncolytic virotherapy, and immunotherapy. These new therapies are in preclinical and investigational stages. They may not substitute the conventional therapies; they may not be the ultimate elixir for this deadly disease. However, in the coming years, they are likely to have synergistic and complimentary roles alongside conventional therapies. Through this paper, we have attempted to highlight the rationale behind gene therapy which can be used for cytotoxic approaches, immunomodulation strategy, and targeted toxin delivery in the tumor cell. We have reviewed current available literature and through this paper focus on reporting such therapeutic options, their potential usage, benefits and limitations. |
| format | Article |
| id | doaj-art-ef5ce70a89de4be4914501eaa57ee49c |
| institution | OA Journals |
| issn | 2277-954X 2277-9167 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Thieme Medical and Scientific Publishers Pvt. Ltd. |
| record_format | Article |
| series | Indian Journal of Neurosurgery |
| spelling | doaj-art-ef5ce70a89de4be4914501eaa57ee49c2025-08-20T02:22:26ZengThieme Medical and Scientific Publishers Pvt. Ltd.Indian Journal of Neurosurgery2277-954X2277-91672012-01-01010105406010.4103/2277-9167.94372Novel therapies for high-grade gliomas: A vision for futureVivek TandonSubhashree Mahapatra0Ashok Kumar MahapatraPhD Student, Hannover Medical UniversityThe treatment for high-grade glioma remains an enigma. The standard treatment using surgery, radiation therapy and chemotherapy for such highly malignant lesions has only yielded modest results, in terms of survival and improving the quality of life of patients. Less than 10% of such patients survive beyond two years. All conventional therapies have failed to increase the survival beyond this extent. There has been a growing interest in the molecular approaches for the treatment of high-grade gliomas which include gene therapy, oncolytic virotherapy, and immunotherapy. These new therapies are in preclinical and investigational stages. They may not substitute the conventional therapies; they may not be the ultimate elixir for this deadly disease. However, in the coming years, they are likely to have synergistic and complimentary roles alongside conventional therapies. Through this paper, we have attempted to highlight the rationale behind gene therapy which can be used for cytotoxic approaches, immunomodulation strategy, and targeted toxin delivery in the tumor cell. We have reviewed current available literature and through this paper focus on reporting such therapeutic options, their potential usage, benefits and limitations.http://www.thieme-connect.de/DOI/DOI?10.4103/2277-9167.94372current studiesgene therapymalignant gliomanovel therapy |
| spellingShingle | Vivek Tandon Subhashree Mahapatra Ashok Kumar Mahapatra Novel therapies for high-grade gliomas: A vision for future Indian Journal of Neurosurgery current studies gene therapy malignant glioma novel therapy |
| title | Novel therapies for high-grade gliomas: A vision for future |
| title_full | Novel therapies for high-grade gliomas: A vision for future |
| title_fullStr | Novel therapies for high-grade gliomas: A vision for future |
| title_full_unstemmed | Novel therapies for high-grade gliomas: A vision for future |
| title_short | Novel therapies for high-grade gliomas: A vision for future |
| title_sort | novel therapies for high grade gliomas a vision for future |
| topic | current studies gene therapy malignant glioma novel therapy |
| url | http://www.thieme-connect.de/DOI/DOI?10.4103/2277-9167.94372 |
| work_keys_str_mv | AT vivektandon noveltherapiesforhighgradegliomasavisionforfuture AT subhashreemahapatra noveltherapiesforhighgradegliomasavisionforfuture AT ashokkumarmahapatra noveltherapiesforhighgradegliomasavisionforfuture |